Author: Next Phase Admin

Hot Investor Mandate: VC Firm With Close Ties to Health Insurance Provider Seeks Investments in Devices, Diagnostics, Digital Health, and Healthcare Services

~ Next Phase Admin ~ Leave a comment

An investment firm manages funds for a major health insurance company in the US. The firm seeks to invest in healthcare companies of strategic interest to this insurance company while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in insurtech companies. The firm partners with payers and providers to drive innovation in healthcare, with a focus in medical devices, diagnostics, and AI solutions for providers. 
 
Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices. 
 
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Fund Invests in Seed to Series A Companies in Deeptech and CNS/Neuro Tech Across All Life Science Sectors

~ Next Phase Admin ~ Leave a comment

An early stage VC fund based in the US currently has $250M under management. The group focuses on highly technical, very early stage companies. The typical investment size is between $1M to $2M and they’re open to lead, co-lead and follow. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 

The firm have been highly active in deep tech/ R&D intensive investments, and have a significant biotech portfolio of notable/renowned companies in the industry. 
 
Currently, the firm’s team is focusing on Neuroscience and brain tech, like Neuromodulation, BCI, precision neuroscience, and infra from data driven angles, like AI in drug development, Multi Omics, from Seed to Series A. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Early-Stage Focused VC Firm Invests in Therapeutics Companies Across All Modalities and Indications, With Focus on US and Europe

~ Next Phase Admin ~ Leave a comment

An early-stage venture capital firm headquartered in the US invests in life science and healthcare companies at Seed and potentially Series A stages. The firm also has the ability to incubate companies. The firm can act as a lead investor for the Seed round and can co-lead or follow for Series A. Typical check sizes range between USD $50k-500k. The firm is open to global companies but has a strong focus on the U.S. and Europe. 
 
The firm is mainly interested in therapeutics and is agnostic with modalities. The firm is opportunistic in terms of medical devices and life science tools. The firm is indication-agnostic. Companies of interest are typically in in-development or clinical trial stages. 
 
As the firm like to be hands on and are active investors, they prefer to take a board or observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Is the NIH Freeze Thawing?

~ Next Phase Admin ~ Leave a comment

By Sougato Das, President and COO, Life Science Nation (LSN)

Sougato-DasOn January 23rd, the Trump administration suspended research-grant reviews, scientist travel, external communications, and training at the NIH, causing concern in the worldwide health research community. This included a temporary freeze on 80% of the NIH’s $47-billion budget, much of which goes to funding early-stage research (the NIH awards more than 60,000 grants every year, supporting at least 300,000 researchers).

Four days later, a clarification was issued: “Procurement, contracting, traveling and hiring at NIH are continuing for anything directly related to human safety, human or animal healthcare, security, biosafety, biosecurity and IT security.” No new studies were being launched, but purchasing and hiring for studies before January 20th would continue. Additionally, essential expenditures for ongoing research and patient care, such as laboratory supplies and necessary travel for treatment or research continuation, were permitted. Finally, operations for existing research discussions and necessary travel would be allowed.

According to a memo obtained by NPR, the restrictions were to be lifted on February 1st. During this time, we saw posts on LinkedIn from startups and their investors alike that SBIR/STTR awardees couldn’t get already approved funds disbursed to them. By January 30th, NIH researchers had unionized to demand negotiations over the freeze, citing severe limits on their work, career progression and freedom of speech. More recently, many major universities started expressing significant concern, as much of their life science research depends on NIH funding.

To add to this complexity, on January 31st, RFK proposed that the Senate Health Committee (23 senators, 2 with medical degrees) should review NIH study proposals to ensure they are free from bias and flawed methodologies. This caused concerns about the impact on independence and confidentiality of scientific research. Finally, yesterday, a federal judge extended an order blocking the Trump administration from enforcing a sweeping freeze on federal grants. Though non-dilutive funding is a critical component of startup development, now may be the time for investors to step up to fill the gap in the current uncertain environment.

While the impacts of the tumultuous past 2 weeks are yet to be realized, areas such as DEI, socially controversial medical topics, and return on investment are under the most scrutiny. On the last of these topics, Life Science Nation (LSN) helps startups get the funding they need to be successful by tackling the ‘red-headed stepchild’ of the medical world: training scientist CEOs to do sales, marketing, and business development. At LSN we firmly believe that in many cases, it’s not the science that fails but the fundraising, forcing otherwise promising innovations to collapse at the end of the cash runway.

By leveraging our investor database, CRM, BD-assist program, and RESI conferences to connect startups with well-aligned investors and in-licensors, we get startups funded fast, saving them critical time and money. In addition, by taking startups through our training courses, we give them the tools to conduct the 9-18 month road show necessary to get the investment to move their assets forward or grow already on-market products. Getting a better ROI on the portion of our tax revenue that goes to funding medical research is more than achievable, and a key component is turning a scientist in to an entrepreneur.

Conversation with Rob Fraser, CSO, President, and Co-founder of Molecular You: Innovator’s Pitch Challenge Success at RESI JPM

~ Next Phase Admin ~ Leave a comment

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiIn this interview, we spoke with Rob Fraser, CSO, President, and Co-founder of Molecular You, who secured 2nd place in the Innovator’s Pitch Challenge at RESI JPM this past January. Rob shares insights into the company’s journey, their fundraising efforts, and their experience pitching to investors at the conference.

Maximize Your Brand’s Exposure with RESI Sponsorship in 2025 

~ Next Phase Admin ~ Leave a comment

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s (LSN) Redefining Every Stage of Investments (RESI) Conference series continues to connect life science innovators with global investors and in-licensors. With multiple RESI conferences remaining in 2025, now is the ideal time to secure exhibitor and sponsorship opportunities that provide direct engagement with key industry stakeholders.

Why Sponsor RESI?

RESI conferences are designed to foster investment and strategic partnerships across biotech, medtech, diagnostics, and digital health. Sponsorship benefits include:

  • High-Visibility Branding – Your company featured throughout the conference
  • Exhibition Space – Dedicated space to showcase your company
  • Speaking Opportunities – Position yourself as an industry leader through workshop participation
  • Targeted Lead Generation – Comprehensive Access to the Post-RESI Attendee Directory
  • Complimentary Registrations – Expand your team’s presence at RESI events

Upcoming RESI Conferences

  • RESI Europe (Barcelona) – In-person on April 1, followed by virtual partnering on April 2-3
  • RESI Boston (June 2025) – In-person on June 16, followed by virtual partnering on June 17-18
  • RESI Boston (September 2025) – In-person September 17, followed by virtual partnering on September 18-19
  • RESI London (December 2025) – In-person December 4, followed by virtual partnering on December 5-6

Secure your sponsorship or exhibitor package today. Contact the LSN Business Development Team to find the best fit for your brand and maximize your impact at RESI in 2025.


Register-now-button-new

Hot Investor Mandate: Single Family Office Makes Global Investments in Therapeutics Companies Across Various Indications, from Seed to Growth Stage

~ Next Phase Admin ~ Leave a comment

A hybrid family office and operating company based can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year. 
 
The firm is primarily looking for companies in the Therapeutics sector and is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of ophthalmology, dermatology, diabetes, oncology, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are clinical stage, but also capable of supporting companies nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. 
 
The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management and product development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.